Rare PPB-like lung tumors described in two young Labradors

A newly published case report in Veterinary Sciences details two young Labrador Retrievers with pulmonary neoplasms showing pleuropulmonary blastoma-like features, adding rare canine data to a tumor type more familiar in pediatric oncology than in companion animal practice. Both dogs arrived with acute respiratory compromise, including dyspnea and pneumothorax, and both underwent emergency thoracostomy tube placement followed by lung lobectomy. Their outcomes diverged: one remained free of recurrence 20 months after surgery, while the other developed recurrence two years later. (mdpi.com)

What makes the report notable is its rarity. According to the authors’ abstract, only two previous PPB reports in animals had been documented before this publication. That matters because primary lung cancer itself is uncommon in dogs, representing about 1% of canine malignancies, and the great majority of canine primary pulmonary tumors are epithelial, not mesenchymal. In other words, these cases sit well outside the pattern most small-animal clinicians and pathologists expect when they evaluate a lung mass in a dog. (mdpi.com)

The comparative angle is especially important. In people, pleuropulmonary blastoma is a rare childhood lung tumor with cystic, mixed, or solid forms, and presentation can include dyspnea, cough, chest pain, or spontaneous pneumothorax. Human PPB is also closely associated with DICER1 biology. The International PPB/DICER1 Registry notes that nearly all PPB tumors are characterized by DICER1 variation, and recent pathology literature describes PPB as a diagnostic challenge that often benefits from molecular testing and specialized review. (ppbregistry.org)

That context helps explain why this canine report goes beyond a standard case description. The paper specifically emphasizes clinicopathological, molecular, and comparative characterization, suggesting the authors are trying to place these Labrador tumors within a broader cross-species framework rather than simply label them as unusual lung sarcomas. The full author list also includes Kris Ann P. Schultz, a leading figure in the PPB/DICER1 field, which strengthens the paper’s comparative oncology relevance and suggests deliberate alignment with established human PPB expertise. (mdpi.com)

Outside reaction appears limited so far, which is not surprising for a niche case report published within the past few days. Still, the surrounding literature points to why specialists may pay attention. A 2025 canine case report separately described pleuropulmonary blastoma in a dog, while current veterinary oncology guidance continues to stress histopathology, staging, and advanced imaging for internal tumors whose behavior and origin are uncertain. In human medicine, registry-based experts have repeatedly warned that PPB and PPB-like lesions can be mistaken for other cystic or sarcomatous processes, with implications for prognosis and follow-up. (bvajournals.onlinelibrary.wiley.com)

Why it matters: For veterinarians, the practical takeaway is less about immediate protocol changes and more about recognition. In a young dog, especially one presenting with spontaneous pneumothorax and atypical pulmonary lesions, a rare mesenchymal neoplasm may deserve consideration alongside more familiar differentials. These cases also reinforce the value of referral-level pathology review and, where available, molecular characterization. As veterinary oncology moves further into genomic diagnostics, unusual tumors like this may be reclassified more precisely, which could improve prognostication and case matching across institutions. (frontiersin.org)

The report also has comparative significance. Human PPB is part of a broader DICER1-related tumor predisposition landscape that includes other rare neoplasms in the kidney, thyroid, gynecologic tract, brain, and elsewhere. While that inherited syndrome framework does not translate directly to canine patients, identifying PPB-like pathology in dogs could open useful research questions about shared tumor biology, molecular drivers, and whether some canine pulmonary sarcomas have been historically underrecognized or misclassified. That is the kind of signal case report that can reshape diagnostic thinking before it changes treatment algorithms. (pmc.ncbi.nlm.nih.gov)

What to watch: The next step is whether more centers retrospectively identify similar cases in young dogs, publish molecular findings, and clarify whether these tumors represent true canine PPB, a PPB-like subgroup, or a broader DICER1-adjacent comparative oncology category. (mdpi.com)